FridayApr 28, 2023 9:45 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Successful DIAB-A22-1 Diabetes Study Indicates Just One of Several Potential Applications for DehydraTECH(TM) Drug Delivery Platform Technology

Lexaria recently completed its diabetes animal model study, DIAB-A22-1, an ambitious study that explored the potential of its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) for the treatment of diabetes The study showed at least three primary positive outcomes, including weight loss and improved triglyceride and cholesterol levels, with lower doses of DehydraTECH-CBD achieving the most optimum outcome The success of this study inches Lexaria closer to capitalizing on the potential of the diabetes drug market, estimated at $63.1 billion in 2021 It also points to the technology’s effectiveness, particularly following the success of the company’s most ambitious clinical study, HYPER-H21-4, demonstrating the…

Continue Reading

MondayApr 17, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes the Licensed Use of its DehydraTECH(TM) Technology to Complement its Royalty Earnings and Realize Revenue in Advance of Royalties

Chris Bunka, Lexaria’s CEO, has reiterated the company’s commitment to creating value for its shareholders with the licensed use of its patented DehydraTECH(TM) technology Mr. Bunka has noted that Lexaria is already in discussions with interested parties in Europe and North America, a move that presents a critical fiscal opportunity for the company He has emphasized how profitable new licensing agreements could be for the company, presenting additional avenues for Lexaria to generate revenue and create value for its shareholders As the company continues to make a transition toward a more commercial focus in 2023, Bunka notes that licensing will…

Continue Reading

MondayApr 10, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Revolutionizing Drug Delivery Potential for Active Pharmaceutical Ingredients Using Patented DehydraTECH(TM) Technology

DehydraTECH(TM)-enabled drugs and product formats improve the speed of onset, increase bioavailability, increase brain absorption, enhance drug potency, reduce drug administration costs, and mask unwanted tastes, shown effective with a growing number of medical applications Current DehydraTECH studies (animal and human) include hypertension, dementia, oral nicotine, epilepsy, and diabetes Most recently, Lexaria’s DehydraTECH-CBD studies for hypertension have produced positive results, and the company is seeking IND status with the FDA Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has developed a disruptive drug delivery technology with multiple opportunities for success in cannabinoids, oral nicotine and other active…

Continue Reading

WednesdayApr 05, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting Multiple Commercial Applications for Its Patented DehydraTECH(TM) Technology Platform

Lexaria Bioscience, a global innovator in drug delivery platforms, has developed and patented the DehydraTECH(TM) drug delivery platform technology The company has undertaken multiple studies as part of its extensive R&D program involving DehydraTECH, which continues to yield positive results This R&D program is focused on the development of product candidates across four main segments, which represent the platform’s potential commercial applications These segments include the development of DehydraTECH-processed cannabidiol (“CBD”) for hypertension, epilepsy, diabetes and dementia; DehydraTECH-processed oral nicotine; other pharmaceutical areas exploring a wide range of DehydraTECH-processed active molecules; and hemp-derived CBD applications for consumer packaged goods (“CPG”)…

Continue Reading

MondayApr 03, 2023 9:00 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) CEO, Chris Bunka, Confident that 2023 will be Lexaria’s Best Year Ever

Chris Bunka, Lexaria’s CEO, remains confident that 2023 will be Lexaria’s best year ever and has expressed his optimism that the company will continue to build its client base and increase its cash flows as the year progresses In his 2023 letter to stakeholders, the CEO expressed his satisfaction given that the company had delivered on a statement that he made the previous year, lauding his team for meeting objectives that Lexaria had set out to achieve in the 2022 calendar year Through the help of his team, Bunka is committed to making Lexaria one of the top drug delivery…

Continue Reading

CanadianCannabisWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 905.674.5977